Current treatment approaches for Paget's Disease of Bone.
Paget's Disease of Bone (PDB) is the second most common metabolic bone disease following osteoporosis. PDB is characterized by an increase in bone resorption and bone deposition. For this reason antiresorptives were indicated as the ideal therapy for PDB. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more convenient management of this disorder. However, no firm evidence exists to show that bisphosphonates can prevent the complications of PDB, and further work is needed to evaluate the influence of pharmacological therapy on long-term clinical outcomes, so that clinicians can make better-informed choices about the risks and benefits of treatment. This article will focus on the present status and future pharmacological developments in PDB.
Brandi
Maria Luisa
ML
Bone and Mineral Metabolic Unit, Department of Internal Medicine and Careggi Hospital, University of Florence, Florence, Italy. m.brandi@dmi.unifi.it
D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D010001:Osteitis Deformans / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
D050071:Bone Density Conservation Agents; D004164:Diphosphonates